

- NATIONAL FUNDING/ACCESS DECISIONS

- **NICE decisions**

- ▶ Afibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014) NICE TA307

Afibercept in combination with irinotecan and fluorouracil-based therapy is **not** recommended within its marketing authorisation for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.

[www.nice.org.uk/guidance/ta307](http://www.nice.org.uk/guidance/ta307)

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

- **Solution for infusion**

- ▶ **Zaltrap** (Sanofi)

**Afibercept 25 mg per 1 ml** Zaltrap 200mg/8ml concentrate for solution for infusion vials | 1 vial **[PoM]** £591.30 (Hospital only)

Zaltrap 100mg/4ml concentrate for solution for infusion vials | 1 vial **[PoM]** £295.65 (Hospital only)